Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Burkitt Lymphoma 1

Interventions

pembrolizumab 304Carboplatin 155Nivolumab 155Cisplatin 140Cyclophosphamide 132Paclitaxel 128Magnetic Resonance Spectroscopy 98Specimen Handling 95Radiotherapy 91Gemcitabine 87Dexamethasone 85Biopsy 81Ipilimumab 78Doxorubicin 76Docetaxel 75Rituximab 70Etoposide 67atezolizumab 62durvalumab 61Radiation 60Lenalidomide 59Pemetrexed 58Taxes 57Bevacizumab 55Prednisone 55fludarabine 54olaparib 54Vincristine 50Cytarabine 48Fluorouracil 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Laparotomy × 1 year × Clear all
NCT00001337 2025-06-22

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
348 enrolled 15 charts
Lymphoid

Burkitt Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡